AstraZeneca (AZN) has disclosed a new risk, in the Environmental / Social category.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca faces significant business risks if it fails to meet its sustainability targets and regulatory requirements concerning environmental issues. As healthcare systems adopt net-zero climate targets, the scrutiny from investors, governments, and NGOs on AstraZeneca’s environmental performance is intensifying. The company’s use of specific materials in manufacturing is under increased regulation, which could lead to supply chain disruptions and financial impacts if not managed proactively. Additionally, failure to enhance its environmental sustainability could result in reputational damage and a competitive disadvantage, adversely affecting AstraZeneca’s financial outcomes.
Overall, Wall Street has a Strong Buy consensus rating on AZN stock based on 7 Buys.
To learn more about AstraZeneca’s risk factors, click here.